Paper40944804
Tumor microenvironment response to neoadjuvant therapy in breast cancer: insights from single-cell and spatial omics.
Wu Q and 5 others. Med Oncol, 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Tumor microenvironment response to neoadjuvant therapy in breast cancer: insights from single-cell and spatial omics. Papers, record 40944804. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40944804
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Tumor microenvironment response to neoadjuvant therapy in breast cancer: insights from single-cell and spatial omics.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Tumor Microenvironment | Major topic |
| Breast Neoplasms | Major topic |
| Neoadjuvant Therapy | Major topic |
| Single-Cell Analysis | Major topic |
| Humans | |
| Female |
Source PubMed
References150
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29126881 | Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents. | Biochim Biophys Acta Rev Cancer | 2018 | https://conductscience.org/library/papers/29126881 | PubMed |
| 2 | 25214542 | The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. | Ann Oncol | 2015 | https://conductscience.org/library/papers/25214542 | PubMed |
| 3 | 40102282 | Tumor microenvironment: recent advances in understanding and its role in modulating cancer therapies. | Med Oncol | 2025 | https://conductscience.org/library/papers/40102282 | PubMed |
| 4 | 36869384 | Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing. | Genome Med | 2023 | https://conductscience.org/library/papers/36869384 | PubMed |
| 5 | 34579743 | Chemotherapy-triggered changes in stromal compartment drive tumor invasiveness and progression of breast cancer. | J Exp Clin Cancer Res | 2021 | https://conductscience.org/library/papers/34579743 | PubMed |
| 6 | 37278484 | Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2-negative breast cancer. | Cancer Commun (Lond) | 2023 | https://conductscience.org/library/papers/37278484 | PubMed |
| 7 | 37947371 | Revolutionizing the battle against locally advanced breast cancer: A comprehensive insight into neoadjuvant radiotherapy. | Med Res Rev | 2024 | https://conductscience.org/library/papers/37947371 | PubMed |
| 8 | 35501486 | A T cell resilience model associated with response to immunotherapy in multiple tumor types. | Nat Med | 2022 | https://conductscience.org/library/papers/35501486 | PubMed |
| 9 | 34966897 | Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response. | Nat Cancer | 2021 | https://conductscience.org/library/papers/34966897 | PubMed |
| 10 | 33334813 | Cancer-Associated Neurogenesis and Nerve-Cancer Cross-talk. | Cancer Res | 2021 | https://conductscience.org/library/papers/33334813 | PubMed |
| 11 | 31710162 | Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer. | Cancer Sci | 2020 | https://conductscience.org/library/papers/31710162 | PubMed |
| 12 | 29674477 | Blockade of Myeloid-Derived Suppressor Cell Expansion with All-Trans Retinoic Acid Increases the Efficacy of Antiangiogenic Therapy. | Cancer Res | 2018 | https://conductscience.org/library/papers/29674477 | PubMed |
| 13 | 22788954 | Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met. | Breast Cancer Res | 2012 | https://conductscience.org/library/papers/22788954 | PubMed |
| 14 | 27939063 | Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. | Lancet | 2017 | https://conductscience.org/library/papers/27939063 | PubMed |
| 15 | 38614094 | A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response. | Cell Rep Med | 2024 | https://conductscience.org/library/papers/38614094 | PubMed |
| 16 | 32086381 | Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. | Sci Immunol | 2020 | https://conductscience.org/library/papers/32086381 | PubMed |
| 17 | 30927930 | Recent advances in understanding tumor stroma-mediated chemoresistance in breast cancer. | Mol Cancer | 2019 | https://conductscience.org/library/papers/30927930 | PubMed |
| 18 | 39522613 | Estrogens and breast cancer. | Ann Oncol | 2025 | https://conductscience.org/library/papers/39522613 | PubMed |
| 19 | 39875975 | CXCR4 promotes tumor stemness maintenance and CDK4/6 inhibitors resistance in ER-positive breast cancer. | Breast Cancer Res | 2025 | https://conductscience.org/library/papers/39875975 | PubMed |
| 20 | 32460816 | Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer. | Breast Cancer Res | 2020 | https://conductscience.org/library/papers/32460816 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 41379384 | Integrating tumor microenvironment insights into neoadjuvant strategies. | Med Oncol | 2025 | https://conductscience.org/library/papers/41379384 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40944804
GET https://conductscience.org/api/papers/v1/40944804/references?page=2